AstraZeneca’s COPD Triple Combo Drug Succeeds in ETHOS Phase III, Setting Up GSK Showdown
Executive Summary
The triple-combination treatment significantly reduced COPD exacerbations compared to older dual therapies in the Phase III ETHOS study, providing a boost to AstraZeneca as it closes in on approvals in the US and Europe.
You may also be interested in...
Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements
The latest drug development news and highlights from our US FDA Performance Tracker.
Win For AZ's COPD Triple Combo In Bid To Catch GSK
GlaxoSmithKline is streets ahead in the three-in-one COPD market, having received approval last year in the USA and Europe for Trelegy Ellipta, but AstraZeneca's PT010 may provide competition in the future having met six out of seven lung function primary endpoints in a Phase III trial.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.